Lifeboat Foundation

Scientists at Northwestern Medicine are using new advances in CRISPR gene-editing technology to uncover new biology that could lead to longer-lasting treatments and new therapeutic strategies for Human Immunodeficiency Virus (HIV).

The HIV epidemic has been overlooked during the COVID-19 pandemic but represents a critical and ongoing threat to human health with an estimated 1.5 million new infections in the last year alone.

Drug developers and research teams have been searching for cures and new treatment modalities for HIV for over 40 years but are limited by their understanding of how the virus establishes infection in the human body. How does this small, unassuming virus with only 12 proteins—and a genome only a third of the size of SARS-CoV-2—hijack the body’s cells to replicate and spread across systems?

Mojo Vision said it has created a new prototype of its Mojo Lens augmented reality contact lenses. This smart contact lens will bring “invisible computing” to life, the company believes.

The Mojo Lens prototype is a critical milestone for the company in its development, testing, and validation process, and is an innovation positioned at the intersection of smartphones, augmented reality/virtual reality, smart wearables, and health tech.

The prototype includes numerous new hardware features and technologies embedded directly into the lens — advancing its display, communications, eye tracking, and power system.

Almost 1,000 adults and children with type 1 diabetes have been given a potentially life-altering ‘artificial pancreas’ by the NHS in England as part of the first nationwide test into the effectiveness of this technology in the world.

Health and high quality care for all, now and for future generations.

The majority of commercial chemicals that enter the market in the United States every year have insufficient health and safety data. For pesticides, the U.S. Environmental Protection Agency uses a variety of techniques to fill data gaps in order to evaluate chemical hazard, exposure and risk. Nonetheless, public concern over the potential threat that these chemicals pose has grown in recent years, along with the realization that traditional animal-testing methods are not pragmatic by means of speed, economics or ethics. Now, researchers at the George Washington University have developed a new computational approach to rapidly screen pesticides for safety, performance and how long they will endure in the environment. Moreover, and most importantly, the new approach will aid in the design of next-generation molecules to develop safer pesticides.

“In many ways, our tool mimics computational drug discovery, in which vast libraries of chemical compounds are screened for their efficacy and then tweaked to make them even more potent against specific therapeutic targets,” Jakub Kostal, an assistant professor of chemistry at GW and principal investigator on the project, said. “Similarly, we use our systems-based approach to modify pesticides to make them less toxic and more degradable, while, at the same time, making sure they retain good performance. It’s a powerful tool for both industry and regulatory agencies that can help design new, safer analogs of existing commercial agrochemicals, and so protect human life, the environment and industry’s bottom line.”

Using their model, the team analyzed 700 pesticides from the EPA’s pesticide registry. The model considered a pesticide’s likely persistence or degradation in the environment over time, its safety, and how well it performed at killing, repelling or controlling the target problem.

On Valentine’s Day 2022 in Havana, Cuba, I received the Soberana Plus booster shot, one of the island nation’s five homegrown COVID-19 vaccines. The jab had been a long time coming.

For the past year, I had been fixated on the idea of being injected with a made-in-Cuba coronavirus vaccine. While obviously not offering protection against the imperial machinations of my homeland and Cuba’s chief antagonist, the United States, the Cuban serums were at least being developed in the interest of global public health rather than pharmaceutical profit or “vaccine apartheid”, as World Health Organization (WHO) Director General Tedros Adhanom Ghebreyesus has described it.

The story of how I finally got my made-in-Cuba booster in Havana.

Continue reading “How to get a Cuban COVID jab in 1,000 easy steps” »

Despite a wealth of knowledge gained in the past three decades concerning the molecular underpinnings of Alzheimer’s disease (AD), progress towards obtaining effective, disease modifying therapies has proven to be challenging. In this manner, numerous clinical trials targeting the production, aggregation, and toxicity of beta-amyloid, have failed to meet efficacy standards. This puts into question the beta-amyloid hypothesis and suggests that additional treatment strategies should be explored. The recent emergence of CRISPR/Cas9 gene editing as a relatively straightforward, inexpensive, and precise system has led to an increased interest of applying this technique in AD. CRISPR/Cas9 gene editing can be used as a direct treatment approach or to help establish better animal models that more faithfully mimic human neurodegenerative diseases. In this manner, this technique has already shown promise in other neurological disorders, such as Huntington’s disease. The purpose of this review is to examine the potential utility of CRISPR/Cas9 as a treatment option for AD by targeting specific genes including those that cause early-onset AD, as well as those that are significant risk factors for late-onset AD such as the apolipoprotein E4 (APOE4) gene.

Keywords: Alzheimer’s disease, CRISPR/Cas9, Gene editing, Treatment, Huntington’s disease, iPSC neurons.

Alzheimer’s Disease (AD) is a progressive and fatal neurodegenerative disorder that primarily affects older adults and is the most common cause of dementia [1]. Currently it afflicts 5.5 million Americans and that number is expected to triple by 2050. At the present time, it is the third leading cause of death behind heart disease and cancer, with an estimated 700,000 Americans ages65 years will have AD when they die [2]. In addition, the cost of the disease is substantial with $259 billion health care dollars going to manage the disease currently, and by the middle of the century costs are predicted to soar over $1.2 trillion, which will completely bankrupt the healthcare system in the USA [3]. Worldwide, 47 million people live with dementia and that number is projected to increase to more than 131 million by 2050 with an estimated worldwide cost of US $818 billion [4].

Every industry will be affected by quantum computing. They will alter the way business is done and the security systems in place which protect data, how we battle illnesses and create new materials, as well as how we tackle health and climate challenges.

As the race to build the first commercially functional quantum computer heats up, here we discuss a handful of the ways quantum computing will alter our world.

Biomedical Interventions For Substantial Global Health Concerns — Dr. Emilio Emini, Ph.D., CEO, Bill & Melinda Gates Medical Research Institute

Dr. Emilio A. Emini, Ph.D. is the CEO of the Bill & Melinda Gates Medical Research Institute (https://www.gatesmri.org/), a non-profit organization dedicated to the development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited, and he leads the Institute’s research and development of novel products and interventions for diseases disproportionately impacting the world’s most vulnerable populations.

Continue reading “Dr. Emilio Emini, Ph.D. — CEO — Bill & Melinda Gates Medical Research Institute” »

SHANGHAI, March 22 (Reuters) — Not a single country managed to meet the World Health Organization’s (WHO) air quality standard in 2021, a survey of pollution data in 6,475 cities showed on Tuesday, and smog even rebounded in some regions after a COVID-related dip.

The WHO recommends that average annual readings of small and hazardous airborne particles known as PM2.5 should be no more than 5 micrograms per cubic metre after changing its guidelines last year, saying that even low concentrations caused significant health risks.

But only 3.4% of the surveyed cities met the standard in 2021, according to data complied by IQAir, a Swiss pollution technology company that monitors air quality. As many as 93 cities saw PM2.5 levels at 10 times the recommended level.